Over the past 7 years, the treatment paradigm for autoimmune and inflammatory diseases has undergone a sea of change…
From the dominance of one biologic therapy class pre 2015, we now have a vast and growing number of treatment options – from advanced therapies including biosimilars, to newer therapy classes with more targeted modes of action. At the same time, stakeholder dynamics continue to evolve as HCP, payer and patient voices grow.
In this webinar, Ipsos’ autoimmune disease experts share a holistic (physician & payer) view of the rapidly evolving therapy landscape in Europe and the learnings and considerations for future success. Specifically, they focus on:
- The past: biosimilar TNF options increase competition and decrease prices with prescribing and procurement driven by “best value”, but how is “best value” defined?
- The present: with JAKs bringing safety concerns, does convenience come at a cost?
- The future: with different therapy classes fighting it out both within and across indications, how will pharma have to rethink its strategy?